INmune Bio upgraded to Buy from Neutral at Lucid Capital
Lucid Capital upgraded INmune Bio (INMB) to Buy from Neutral with a price target of $9, up from $2. The firm is now factoring into the model the company’s CORDStrom therapy for recessive dystrophic epidermolysis bullosa. Lucid cites the expanded scope of value drivers across INmune’s pipeline for the upgrade.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Read More on INMB:
- Inmune Bio Completes Early INKmune Trial in Advanced Prostate Cancer: What Investors Should Watch Next
- INmune Bio Highlights CORDStrom RDEB Program and IP Strength
- INmune Bio Advances XPro Toward Registrational Alzheimer’s Study
- INmune Bio to Present New CORDStrom Phase III Data
- INmune Bio Advances CORDStrom Toward Rare Disease Commercialization
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Should You Consider Investing in Rio Tinto Shares Following a 64.9% Surge Over the Past Six Months?
Chubb to serve as lead US insurer for Gulf shipping amid Iran war
US February budget deficit flat at $308 billion as tariff revenues not yet hit by court ruling
5 Best Crypto Presale Projects to Buy Before April’s Market Turn: #1 Leads the Market With 190% Rally Ahead of March Launch
Trending news
MoreCrypto prices
More
